File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Check point inhibitors as therapies for infectious diseases

TitleCheck point inhibitors as therapies for infectious diseases
Authors
Issue Date2017
Citation
Current Opinion in Immunology, 2017, v. 48, p. 61-67 How to Cite?
Abstract© 2017 The recent successes of immune check point targeting therapies in treating cancer patients has driven a resurgence of interest in targeting these pathways in chronically infected patients. While still in early stages, basic and clinical data suggest that blockade of CTLA-4 and PD-1 can be beneficial in the treatment of chronic HIV, HBV, and HCV infection, as well as other chronic maladies. Furthermore, novel inhibitory receptors such as Tim-3, LAG-3, and TIGIT are the potential next wave of check points that can be manipulated for the treatment of chronic infection. Blockade of these pathways influences more than simply T cell responses, and may provide new therapeutic options for chronically infected patients.
Persistent Identifierhttp://hdl.handle.net/10722/293042
ISSN
2020 Impact Factor: 7.486
2020 SCImago Journal Rankings: 3.863
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCox, Maureen A.-
dc.contributor.authorNechanitzky, Robert-
dc.contributor.authorMak, Tak W.-
dc.date.accessioned2020-11-17T14:57:45Z-
dc.date.available2020-11-17T14:57:45Z-
dc.date.issued2017-
dc.identifier.citationCurrent Opinion in Immunology, 2017, v. 48, p. 61-67-
dc.identifier.issn0952-7915-
dc.identifier.urihttp://hdl.handle.net/10722/293042-
dc.description.abstract© 2017 The recent successes of immune check point targeting therapies in treating cancer patients has driven a resurgence of interest in targeting these pathways in chronically infected patients. While still in early stages, basic and clinical data suggest that blockade of CTLA-4 and PD-1 can be beneficial in the treatment of chronic HIV, HBV, and HCV infection, as well as other chronic maladies. Furthermore, novel inhibitory receptors such as Tim-3, LAG-3, and TIGIT are the potential next wave of check points that can be manipulated for the treatment of chronic infection. Blockade of these pathways influences more than simply T cell responses, and may provide new therapeutic options for chronically infected patients.-
dc.languageeng-
dc.relation.ispartofCurrent Opinion in Immunology-
dc.titleCheck point inhibitors as therapies for infectious diseases-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.coi.2017.07.016-
dc.identifier.pmid28865357-
dc.identifier.scopuseid_2-s2.0-85028698905-
dc.identifier.volume48-
dc.identifier.spage61-
dc.identifier.epage67-
dc.identifier.eissn1879-0372-
dc.identifier.isiWOS:000416299500011-
dc.identifier.issnl0952-7915-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats